Pharma

Accelerating Climate Action, 11 Boston and Cambridge Institutions Collaborate to Invest in Wind and Solar Power

November 20, 2024

Lumicell’s Board of Directors Appoints Howard Hechler as Chief Executive Officer

November 13, 2024

Myrobalan Therapeutics Appoints Robin Kleiman Ph.D., as Chief Scientific Officer

October 31, 2024

THIS WEEK'S STORIES

BrightHeart Secures FDA Clearance for First AI Software Revolutionizing Prenatal Fetal Heart Ultrasound Evaluations

November 18, 2024

Kevin Krause named President and CEO of ArrePath

November 19, 2024

Thomas Manley, M.D. Joins Rondo Therapeutics as Chief Medical Officer to Lead Clinical Development of Rondo Therapeutics’ Bispecific Antibody Programs

November 19, 2024

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Aptar Pharma Enters into Exclusive Agreement with Cambridge Healthcare Innovations to Commercialize the Quattrii Dry Powder Inhaler Platform

Scripps Research Advances Breakthrough Regenerative Medicines to Reverse Aging-Related Diseases

Bayer and Liveo Research Launch First-of-its-Kind Blister Packaging with Improved Environmental Footprint

Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

Most Read

Bayer Announces ‘Project Enhanced S3’ to Enable Companies to Realize Additional Sustainability Value from Carbon Removal Projects

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Hyperfine Swoop® Portable MR Brain Imaging System Meets New Standards Recently Issued by CMS-Approved Accrediting Body

Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates

EDITOR PICKS